Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06287203 · ClinicalTrials.gov registry record · NA

Novel Prevention Intervention Program to Reduce Risky Patterns of Substance Use Among Emerging Adults

A NA study of Substance Use, sponsored by Rutgers, The State University of New Jersey.

Active
Registry status
NA
Development phase
660
Enrollment target
1
Study location

NCT06287203 is a NA study of Substance Use that is active but no longer recruiting, run by Rutgers, The State University of New Jersey. The registered enrollment target is 660 participants, below the 1,253-participant average among 88 other Substance Use trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06287203, a NA study of Substance Use, is active but no longer recruiting, sponsored by Rutgers, The State University of New Jersey.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
660 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to test whether completion of a new personalized feedback program is associated with reductions in risky substance use among emerging adults (18-25 years of age).

Conditions Studied

Interventions

  • BEHAVIORAL Addiction Risk Feedback Program

Study Locations (1)

New Jersey

  • Rutgers Robert Wood Johnson Medical School - Piscataway

Trial Details

FieldValue
Enrollment Target 660 participants
Start Date 2024-04-12
Est. Completion 2026-01-31
Phase NA

What the Registry Record Tells You About NCT06287203

The ClinicalTrials.gov registry entry for NCT06287203 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 660 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,253-participant average among 88 other Substance Use trials with a reported enrollment target (47% lower). The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Substance Use appearing as the primary indexed condition, and to 1 intervention - of which Addiction Risk Feedback Program is the first listed.

NCT06287203 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT06287203 about?

NCT06287203 is a clinical study titled "Novel Prevention Intervention Program to Reduce Risky Patterns of Substance Use Among Emerging Adults". The purpose of this research study is to test whether completion of a new personalized feedback program is associated with reductions in risky substance use among emerging adults (18-25 years of age).

What is the current status of trial NCT06287203?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 660 participants. The study started on 2024-04-12. Estimated completion is 2026-01-31.

What conditions does trial NCT06287203 study?

This clinical trial studies the following conditions: Substance Use.

What interventions are being tested in trial NCT06287203?

The interventions under investigation include: Addiction Risk Feedback Program (BEHAVIORAL).

Who is sponsoring clinical trial NCT06287203?

This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06287203 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Substance Use

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.